NSCLC Stage IIIA/BPhase 2NCT07917767
A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of Resectable Non-small Cell Lung Cancer
A Phase 2 study testing Cohort A and Cohort B in people with NSCLC Stage IIIA/B and NSCLC Stage II, run by Tang-Du Hospital.
Trial summary
This multicenter, prospective, randomized controlled study aims to evaluate the efficacy and safety of different durations of neoadjuvant treatment with a PD-1 inhibitor, ipilimumab, and chemotherapy in patients with resectable non-small cell lung cancer (NSCLC). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- NSCLC Stage IIIA/B, NSCLC Stage II
- What is being tested?
- Cohort A and Cohort B
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- No sites listed yet
- Study dates
- 30 Nov 2026to 31 Dec 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must meet all of the following inclusion criteria to be eligible for enrollment in this study:
- Patients must sign a written informed consent form (ICF) and be able to comply with protocol-specified visits and related procedures.
- Age ≥18 years.
- Cytologically or histologically confirmed primary non-small cell lung cancer (NSCLC), including adenocarcinoma and squamous cell carcinoma.
- Clinical stage IIB (primary tumor >4 cm), IIIA, or IIIB (limited to resectable N2 disease) according to the ninth edition of the lung cancer TNM staging classification established by the International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC). Resectable N2 disease is defined as non-bulky (short-axis diameter <3 cm), discrete, or single-station N2 involvement. Pathological confirmation is required if N2 or N3 involvement is clinically suspected.
- Patients with non-squamous NSCLC must undergo molecular testing confirming the absence of sensitizing epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. Molecular testing is not mandatory for patients with squamous NSCLC; however, patients with known sensitizing EGFR mutations or ALK rearrangements must not be enrolled.
Show all 19Show fewer
- Patients must be considered suitable for curative-intent surgical resection. Pulmonary function must meet the requirements for the planned lung resection (forced expiratory volume in one second [FEV1] ≥50% of the predicted value and maximal voluntary ventilation [MVV] ≥50% of the predicted value), with no contraindications to surgery.
- Patients must be able to provide sufficient qualified tumor tissue specimens for programmed death-ligand 1 (PD-L1) testing during screening.
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
- No prior systemic antitumor therapy or local radiotherapy for NSCLC.
- Adequate organ and bone marrow function, with laboratory values obtained within 7 days before enrollment meeting the following requirements. No blood components, hematopoietic growth factors, albumin, or other intravenous or subcutaneous medications intended to correct hematologic, hepatic, or renal dysfunction are permitted within 14 days before laboratory testing. The specific requirements are as follows:
- Adequate hematologic function: Absolute neutrophil count ≥1.5 × 10⁹/L, platelet count ≥100 × 10⁹/L, and hemoglobin ≥100 g/L.
- Adequate hepatic function: Total bilirubin ≤1.5 × the upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN; and albumin (ALB) ≥35 g/L.
- Adequate renal function: Serum creatinine (Scr) ≤1.5 × ULN; creatinine clearance (CrCl) ≥60 mL/min, calculated using the Cockcroft-Gault formula; and urine protein (UPRO) <2+ on routine urinalysis or 24-hour urinary protein <1 g.
- Adequate coagulation function: International normalized ratio (INR) ≤1.5 × ULN and prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤1.5 × ULN within 7 days before study treatment.
- Female patients of childbearing potential must have a negative urine or serum pregnancy test within 7 days before the first administration of study treatment. If the urine pregnancy test is positive, a serum pregnancy test is required.
- Male and female patients at risk of conception must use highly effective contraception (defined as a method with an annual failure rate of <1%) and continue contraception for at least 180 days after discontinuation of study treatment.
- Note: Abstinence is acceptable as a contraceptive method if it is the patient's usual lifestyle and preferred method of contraception.
Who cannot join
- Patients meeting any of the following exclusion criteria will not be eligible for enrollment in this study:
- Pathological evidence of small cell carcinoma, neuroendocrine carcinoma, sarcoma, lymphoepithelioma-like carcinoma, salivary gland tumors, or mesenchymal tumor components.
- Tumor invasion of the diaphragm, mediastinum, heart, pericardium, major blood vessels (e.g., aorta), trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina.
- Superior sulcus tumor.
- Presence of tumor nodules in the contralateral lung. If contralateral pulmonary tumor nodules are clinically suspected, biopsy confirmation is required.
- Confirmed or suspected brain metastases.
Show all 43Show fewer
- Current participation in an interventional clinical study involving treatment, or receipt of another investigational drug or investigational medical device treatment within 4 weeks before randomization.
- Prior treatment with anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), anti-programmed death-ligand 2 (PD-L2), or anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) agents; any other agents targeting T-cell costimulatory or immune checkpoint pathways (e.g., OX40 or CD137); or adoptive cellular immunotherapy.
- Receipt of traditional Chinese herbal medicines or Chinese patent medicines with antitumor indications, or immunomodulatory agents (including thymosin preparations, interferons, or interleukins), within 2 weeks before randomization.
- Receipt of a live attenuated vaccine within 4 weeks before randomization or planned receipt of a live attenuated vaccine during the study.
- Note: Injectable inactivated seasonal influenza vaccines are permitted; however, live attenuated influenza vaccines are not permitted.
- Patients requiring long-term systemic corticosteroid therapy or receiving any other form of immunosuppressive therapy within 7 days before randomization.
- Note: Intranasal, inhaled, or other topical corticosteroids; systemic corticosteroids at physiological doses (≤10 mg/day of prednisone or equivalent); or corticosteroids administered as premedication (e.g., for prevention of contrast media hypersensitivity) are permitted.
- History of noninfectious pneumonitis requiring corticosteroid treatment within 1 year before randomization or current interstitial lung disease.
- Active autoimmune disease requiring systemic treatment (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years before randomization, including but not limited to inflammatory bowel disease, such as ulcerative colitis or Crohn's disease; diverticulitis; celiac disease; systemic lupus erythematosus; sarcoidosis; Wegener's syndrome (granulomatosis with polyangiitis); Graves' disease; rheumatoid arthritis; multiple sclerosis; vasculitis; glomerulonephritis; antiphospholipid syndrome; hypophysitis; or uveitis.
- Replacement therapy (e.g., thyroxine, insulin, or physiological doses of corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment. Patients with positive autoimmune antibodies may be enrolled only after investigator assessment confirms the absence of an autoimmune disease requiring systemic treatment.
- Primary immunodeficiency disorder.
- History of or current myocarditis.
- Failure to adequately recover from toxicities and/or complications caused by any intervention before randomization (i.e., toxicity of Grade >1 or failure to recover to the baseline level required by the protocol).
- Peripheral neuropathy of Grade ≥2.
- Hereditary bleeding tendency or coagulation disorder, or a history of thrombosis: any arterial thrombosis, embolism, or ischemic event within 6 months before randomization, such as myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, or pulmonary embolism. History of deep vein thrombosis or any other serious thromboembolic event within 3 months before randomization. Thrombosis associated with an implanted venous access port or catheter, or superficial venous thrombosis, is not considered a serious thromboembolic event.
- Uncontrolled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg); history of hypertensive crisis or hypertensive encephalopathy; or uncontrolled hyperglycemia (fasting blood glucose >8.9 mmol/L).
- Patients with non-squamous NSCLC who are unable or unwilling to receive folic acid or vitamin B12 supplementation.
- Any unstable systemic disease or concomitant medical condition, including but not limited to:
- Active infection (requiring anti-infective treatment or receipt of systemic anti-infective medication within 1 week before randomization).
- Congestive heart failure [New York Heart Association (NYHA) functional class ≥II].
- Severe arrhythmia requiring medication, or severe hepatic, renal, or metabolic disease.
- Untreated coronary artery disease.
- History of gastrointestinal perforation and/or fistula, intestinal obstruction, extensive bowel resection, or long-term chronic diarrhea within 6 months before randomization.
- History of solid organ or hematopoietic transplantation.
- Known history of human immunodeficiency virus (HIV) infection (i.e., positive HIV-1/2 antibodies) or known active syphilis.
- Active tuberculosis, including but not limited to pulmonary tuberculosis, or tuberculosis currently requiring medical intervention.
- Active hepatitis B.
- Patients with hepatitis B who meet the following criteria are eligible for enrollment: hepatitis B surface antigen (HBsAg)-positive or hepatitis B core antibody (anti-HBc)-positive, with an HBV viral load <1,000 copies/mL, <200 IU/mL, or below the lower limit of detection before randomization.
- HBsAg-positive patients must receive anti-HBV treatment throughout the study drug treatment period to prevent HBV reactivation.
- For patients who are anti-HBc-positive, HBsAg-negative, hepatitis B surface antibody (anti-HBs)-negative, and HBV DNA-negative, prophylactic anti-HBV treatment is not required; however, close monitoring for viral reactivation is necessary.
- Active hepatitis C (positive hepatitis C virus [HCV] antibody and HCV RNA level above the lower limit of detection).
- History of a confirmed malignancy other than NSCLC within 5 years before randomization, except for adequately treated carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin, localized prostate cancer after curative surgery, ductal carcinoma in situ after curative surgery, or papillary thyroid carcinoma after curative surgery.
- Known hypersensitivity to the active ingredients and/or any excipients of the PD-1 monoclonal antibody, ipilimumab N01, and/or the selected chemotherapy regimen (pemetrexed plus carboplatin/cisplatin for non-squamous NSCLC; nab-paclitaxel plus carboplatin/cisplatin for squamous NSCLC).
- Female patients who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
- Known psychiatric disorders or substance abuse that may affect compliance with study requirements, or a history of alcohol abuse.
- Any medical history, disease, treatment, or laboratory abnormality that may interfere with study results, prevent the patient from participating in the study throughout its duration, or, in the investigator's opinion, make study participation inconsistent with the patient's best interests.
- Any localized or systemic disease unrelated to malignancy, or any secondary reaction to cancer, that may result in increased medical risk and/or uncertainty in survival assessment.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Prospective Cohort Study of Perioperative PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer
This multicenter, prospective, randomized controlled study aims to evaluate the efficacy and safety of different durations of neoadjuvant treatment with a PD-1 inhibitor, ipilimumab, and chemotherapy in patients with resectable non-small cell lung cancer (NSCLC). A total of 90 treatment-naïve patients with clinical stage IIA (primary tumor >4 cm) to stage IIIB (limited to resectable N2 disease) NSCLC will be enrolled and randomly assigned in a 1:1 ratio to Cohort A (n=45) or Cohort B (n=45).
Patients in Cohort A will receive two cycles of a PD-1 inhibitor plus chemotherapy and one cycle of ipilimumab, whereas patients in Cohort B will receive four cycles of a PD-1 inhibitor plus chemotherapy and two cycles of ipilimumab. The PD-1 inhibitor will be administered intravenously at 200 mg every three weeks, and ipilimumab at 1 mg/kg every six weeks. Chemotherapy regimens will be selected according to histological subtype: pemetrexed plus carboplatin or cisplatin for non-squamous NSCLC, and nab-paclitaxel plus carboplatin or cisplatin for squamous NSCLC.
Read more
Following neoadjuvant treatment, eligible patients will undergo curative-intent surgery within 22-42 days after the last treatment dose. Investigator-selected adjuvant therapy will begin 29-42 days after surgery. Tumor assessments will be performed according to RECIST version 1.1, with postoperative follow-up for up to five years.
The primary endpoint is the pathological complete response (pCR) rate, with treatment safety also being evaluated.
- Conditions
- NSCLC Stage IIIA/B, NSCLC Stage II
- Being tested
- Cohort A, Cohort B
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cohort ADrug
Participants in Cohort A will receive 2 cycles of neoadjuvant dual immunotherapy plus platinum-based doublet chemotherapy. The regimen consists of a PD-1 inhibitor (200 mg intravenously every 3 weeks for 2 cycles), ipilimumab (1 mg/kg intravenously every 6 weeks for 1 cycle), and 2 cycles of chemotherapy. Patients with non-squamous NSCLC will receive pemetrexed plus carboplatin or cisplatin, while those with squamous NSCLC will receive nab-paclitaxel plus carboplatin or cisplatin. Eligible patients will undergo curative-intent surgery following neoadjuvant treatment.
Cohort BDrug
Participants in Cohort B will receive 4 cycles of neoadjuvant dual immunotherapy plus platinum-based doublet chemotherapy. The regimen consists of a PD-1 inhibitor (200 mg intravenously every 3 weeks for 4 cycles), ipilimumab (1 mg/kg intravenously every 6 weeks for 2 cycles), and 4 cycles of chemotherapy. Patients with non-squamous NSCLC will receive pemetrexed plus carboplatin or cisplatin, while those with squamous NSCLC will receive nab-paclitaxel plus carboplatin or cisplatin. Eligible patients will undergo curative-intent surgery following neoadjuvant treatment.
| Study group | Role | What they receive |
|---|---|---|
| 2-Cycle Neoadjuvant Dual Immunotherapy Plus Chemotherapy | Experimental | Not described Receives: Drug: Cohort A |
| 4-Cycle Neoadjuvant Dual Immunotherapy Plus Chemotherapy | Experimental | Not described Receives: Drug: Cohort B |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathological Complete Response (pCR) Rate
The pCR rate is defined as the proportion of participants with no residual viable tumor cells in the resected primary tumor and sampled regional lymph nodes (ypT0N0), as determined by histopathological examination following neoadjuvant treatment and surgical resection. The pCR rate will be assessed separately in each treatment cohort.
Measured: At the time of surgery, approximately 20 weeks after randomization
Secondary outcomes (5)
Major Pathological Response (MPR) Rate
The MPR rate is defined as the proportion of participants with 10% or less residual viable tumor cells in the resected primary tumor, as determined by histopathological examination following neoadjuvant treatment and surgical resection. The MPR rate will be assessed separately in each treatment cohort.
Measured: At the time of surgery, approximately 20 weeks after randomization
R0 Resection Rate
The R0 resection rate is defined as the proportion of participants who achieve complete surgical resection with microscopically negative resection margins, as confirmed by postoperative histopathological examination.
Measured: At the time of surgery, approximately 20 weeks after randomization
On-Schedule Surgery Completion Rate
The on-schedule surgery completion rate is defined as the proportion of participants who undergo curative-intent surgical resection within the protocol-specified window of 22 to 42 days after the last dose of neoadjuvant treatment.
Measured: Within 22 to 42 days after the last dose of neoadjuvant treatment
Safety and Tolerability of Neoadjuvant Treatment
Safety and tolerability will be evaluated based on the incidence and severity of adverse events (AEs), serious adverse events (SAEs), and treatment-related adverse events (TRAEs), assessed according to NCI-CTCAE version 5.0. The relationship of adverse events to study treatment will be determined by the investigator. Perioperative complications will be assessed using the Clavien-Dindo classification, and perioperative mortality will also be recorded.
Measured: From the first dose of neoadjuvant treatment through 90 days after surgery
Health-Related Quality of Life (HRQoL)
Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and Lung Cancer Module 29 (EORTC QLQ-LC29). These questionnaires evaluate global health status, physical and functional well-being, lung cancer-related symptoms, and treatment-related adverse effects. Scores will be transformed to a 0-100 scale according to the EORTC scoring guidelines. Higher global health and functional scores indicate better quality of life, whereas higher symptom scores indicate greater symptom burden.
Measured: During the first 12 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2026
- Study start30 Nov 2026 (estimated)
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NSCLC Stage IIIA/BStudies of the same condition, open and under way.
- More trials run by Tang-Du HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tang-Du Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07917767
- Sponsor's protocol ID
- JG-01-KYLX-NSCLC
- Status last verified
- Oct 2026
- First submitted
- 28 Oct 2026
- Last updated
- 5 Nov 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Cohort Study of Perioperative PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT07917767
- Acronym / sponsor ID
- JG-01-KYLX-NSCLC
- Conditions
- NSCLC Stage IIIA/B, NSCLC Stage II
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Tang-Du HospitalUniversity, hospital or other
- Study start
- 30 Nov 2026 (estimated)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 5 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multicenter, prospective, randomized controlled study aims to evaluate the efficacy and safety of different durations of neoadjuvant treatment with a PD-1 inhibitor, ipilimumab, and chemotherapy in patients with resectable non-small cell lung cancer (NSCLC). A total of 90 treatment-naïve patients with clinical stage IIA (primary tumor >4 cm) to stage IIIB (limited to resectable N2 disease) NSCLC will be enrolled and randomly assigned in a 1:1 ratio to Cohort A (n=45) or Cohort B (n=45).
Patients in Cohort A will receive two cycles of a PD-1 inhibitor plus chemotherapy and one cycle of ipilimumab, whereas patients in Cohort B will receive four cycles of a PD-1 inhibitor plus chemotherapy and two cycles of ipilimumab. The PD-1 inhibitor will be administered intravenously at 200 mg every three weeks, and ipilimumab at 1 mg/kg every six weeks. Chemotherapy regimens will be selected according to histological subtype: pemetrexed plus carboplatin or cisplatin for non-squamous NSCLC, and nab-paclitaxel plus carboplatin or cisplatin for squamous NSCLC.
Following neoadjuvant treatment, eligible patients will undergo curative-intent surgery within 22-42 days after the last treatment dose. Investigator-selected adjuvant therapy will begin 29-42 days after surgery. Tumor assessments will be performed according to RECIST version 1.1, with postoperative follow-up for up to five years.
The primary endpoint is the pathological complete response (pCR) rate, with treatment safety also being evaluated.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 2-Cycle Neoadjuvant Dual Immunotherapy Plus Chemotherapy | Experimental | Drug: Cohort A |
| 4-Cycle Neoadjuvant Dual Immunotherapy Plus Chemotherapy | Experimental | Drug: Cohort B |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (19 listed)
- Patients must meet all of the following inclusion criteria to be eligible for enrollment in this study:
- Patients must sign a written informed consent form (ICF) and be able to comply with protocol-specified visits and related procedures.
- Age ≥18 years.
- Cytologically or histologically confirmed primary non-small cell lung cancer (NSCLC), including adenocarcinoma and squamous cell carcinoma.
- Clinical stage IIB (primary tumor >4 cm), IIIA, or IIIB (limited to resectable N2 disease) according to the ninth edition of the lung cancer TNM staging classification established by the International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC). Resectable N2 disease is defined as non-bulky (short-axis diameter <3 cm), discrete, or single-station N2 involvement. Pathological confirmation is required if N2 or N3 involvement is clinically suspected.
Key exclusion criteria (43 listed)
- Patients meeting any of the following exclusion criteria will not be eligible for enrollment in this study:
- Pathological evidence of small cell carcinoma, neuroendocrine carcinoma, sarcoma, lymphoepithelioma-like carcinoma, salivary gland tumors, or mesenchymal tumor components.
- Tumor invasion of the diaphragm, mediastinum, heart, pericardium, major blood vessels (e.g., aorta), trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina.
- Superior sulcus tumor.
- Presence of tumor nodules in the contralateral lung. If contralateral pulmonary tumor nodules are clinically suspected, biopsy confirmation is required.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cohort AParticipants in Cohort A will receive 2 cycles of neoadjuvant dual immunotherapy plus platinum-based doublet chemotherapy. The regimen consists of a PD-1 inhibitor (200 mg intravenously every 3 weeks for 2 cycles), ipilimumab (1 mg/kg intravenously every 6 weeks for 1 cycle), and 2 cycles of chemotherapy. Patients with non-squamous NSCLC will receive pemetrexed plus carboplatin or cisplatin, while those with squamous NSCLC will receive nab-paclitaxel plus carboplatin or cisplatin. Eligible patients will undergo curative-intent surgery following neoadjuvant treatment. | Drug | 2-Cycle Neoadjuvant Dual Immunotherapy Plus Chemotherapy |
| Cohort BParticipants in Cohort B will receive 4 cycles of neoadjuvant dual immunotherapy plus platinum-based doublet chemotherapy. The regimen consists of a PD-1 inhibitor (200 mg intravenously every 3 weeks for 4 cycles), ipilimumab (1 mg/kg intravenously every 6 weeks for 2 cycles), and 4 cycles of chemotherapy. Patients with non-squamous NSCLC will receive pemetrexed plus carboplatin or cisplatin, while those with squamous NSCLC will receive nab-paclitaxel plus carboplatin or cisplatin. Eligible patients will undergo curative-intent surgery following neoadjuvant treatment. | Drug | 4-Cycle Neoadjuvant Dual Immunotherapy Plus Chemotherapy |
Primary outcome
Pathological Complete Response (pCR) Rate
Time frame: At the time of surgery, approximately 20 weeks after randomization
The pCR rate is defined as the proportion of participants with no residual viable tumor cells in the resected primary tumor and sampled regional lymph nodes (ypT0N0), as determined by histopathological examination following neoadjuvant treatment and surgical resection. The pCR rate will be assessed separately in each treatment cohort.
5 secondary outcomes
Major Pathological Response (MPR) Rate
Time frame: At the time of surgery, approximately 20 weeks after randomization
R0 Resection Rate
Time frame: At the time of surgery, approximately 20 weeks after randomization
On-Schedule Surgery Completion Rate
Time frame: Within 22 to 42 days after the last dose of neoadjuvant treatment
Safety and Tolerability of Neoadjuvant Treatment
Time frame: From the first dose of neoadjuvant treatment through 90 days after surgery
Health-Related Quality of Life (HRQoL)
Time frame: During the first 12 months after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Individual participant dataSharing planned: Undecided
Related trials for NSCLC Stage IIIA/B
Active, not recruitingPhase 2
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
RecruitingObservational study
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation
RecruitingPhase 2
Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Lung Cancer Non-Small Cell Cancer (NSCLC)
Not yet recruitingObservational study
Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: A Multi - Omics Perspective
NSCLC Stage IIIA/B, NSCLC Stage II
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Cohort A and Cohort B in people with NSCLC Stage IIIA/B and NSCLC Stage II, run by Tang-Du Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 43 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiaolong Yan (8615991269383, yanxiaolong@fmmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pathological Complete Response (pCR) Rate (time frame: At the time of surgery, approximately 20 weeks after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.